Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. CSX
7. IBM
8. KNX
9. AMD
10. INTC

Go back to Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
(NYSE: BHVN) Delayed: 14.38 -0.37 (2.51%)
Previous Close $14.75    52 Week High $ 
Open $14.65    52 Week Low $ 
Day High $14.86    P/E N/A 
Day Low $14.37    EPS $ 
Volume 639,021